Vichinsky E, Hoppe CC, Ataga KI, et al. Results from the randomized placebo-controlled phase 3 HOPE trial of voxelotor in adults and adolescents with sickle cell disease. 24th Congress of EHA, abstract S147.
Rivaroxaban vermindert VTE bij ambulante patiënten met kanker
dec 2018 | Benigne hematologie